EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pharmacology of orismilast, a potent and selective PDE4 inhibitor

Jonathan I Silverberg iD, Lars E French iD, Richard B Warren, Bruce Strober iD, Kim Kjøller, Morten O A Sommer, Philippe Andres, Jakob Felding, Anne Weiss, Deniz Tutkunkardas iD, Tine Skak-Nielsen, Emma Guttman iD

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.18818 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Jonathan I Silverberg und 11 weiteren Autor:innen. Beteiligte Einrichtung: George Washington University School of Medicine and Health Sciences, District of Columbia, Washington, USA. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: LEO Pharma A/S, UNION therapeutics A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There remains an unmet need for oral medications that are safe and efficacious for long‐term management of chronic inflammatory skin diseases (CISD). Inhibition of phosphodiesterase 4 (PDE4) can modulate a broad range of pro‐inflammatory cytokines that play a major role in CISD pathogenesis. Orismilast is a second generation PDE4 inhibitor in clinical development for CISD treatment.

Objectives

The objective of this study was to examine the PDE4 enzymatic activity and anti‐inflammatory effects of orismilast in vitro , ex vivo , and in vivo.

Methods

The PDE1‐11 enzymatic activity of orismilast was tested in vitro using a single concentration of 308 nM orismilast. The PDE4 selectivity and inhibitory potency was further examined in a radiometric assay. Orismilast was tested on human whole blood and human peripheral blood mononuclear cells (PBMC) to determine effects on its cytokine secretion and inhibition profile ex vivo. Orismilast was orally administered in a murine model of chronic oxazolone‐induced ear skin inflammation. Ear thickness, a marker of inflammation, and inflammatory cytokines were analysed.

Results

Orismilast selectively inhibited PDE4 and demonstrated potent inhibition of PDE4B and PDE4D subtype splice variants in vitro. Orismilast inhibited whole blood and PBMC production of tumour necrosis factor α (TNFα), and the secretion of T‐helper (Th)1 (TNFα and IFNγ), Th17 (IL‐22 and IL‐23), and Th2 (IL‐4, IL‐5, and IL‐13) related cytokines in PBMC. In vivo , 10 and 30 mg/kg doses of orismilast significantly reduced ear thickness and inflammation markers ( p < 0.0001, respectively).

Conclusion

Orismilast displayed selective and potent PDE4 inhibition and broad‐spectrum anti‐inflammatory activity in several pre‐clinical models. The results of the study support clinical development of oral orismilast as a novel treatment option for CISD including psoriasis, atopic dermatitis, and hidradenitis suppurativa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 4 InhibitorsHumansMiceAnimalsTumor Necrosis Factor-alphaLeukocytes, MononuclearInflammationAnti-Inflammatory AgentsCytokines

Substanzen

Phosphodiesterase 4 InhibitorsTumor Necrosis Factor-alphaAnti-Inflammatory AgentsCytokines

Autor:innen und Institutionen

  • George Washington University School of Medicine and Health Sciences, District of Columbia, Washington, USA.
  • Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University (LMU) Munich, Munich, Germany. Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller Schoo…
  • Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK.
  • Yale University and Central Connecticut Dermatology, Connecticut, Cromwell, USA.
  • UNION therapeutics, A/S, Hellerup, Denmark.
  • Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark (DTU), Kongens Lyngby, Denmark.

ORCID-Profile: Jonathan I Silverberg, Lars E French, Bruce Strober, Deniz Tutkunkardas, Emma Guttman

Förderung

  • LEO Pharma A/S
  • UNION therapeutics A/S

Zitieren

APA

Silverberg, J. I., French, L. E., Warren, R. B., Strober, B., Kjøller, K., Sommer, M. O. A., Andres, P., Felding, J., Weiss, A., Tutkunkardas, D., Skak-Nielsen, T., & Guttman, E. (2023). Pharmacology of orismilast, a potent and selective PDE4 inhibitor. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.18818

Vancouver

Silverberg JI, French LE, Warren RB, Strober B, Kjøller K, Sommer MOA, et al. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.18818

BibTeX
@article{Silverberg2023,
  author = {Silverberg, Jonathan I and French, Lars E and Warren, Richard B and Strober, Bruce and Kjøller, Kim and Sommer, Morten O A and Andres, Philippe and Felding, Jakob and Weiss, Anne and Tutkunkardas, Deniz and Skak-Nielsen, Tine and Guttman, Emma},
  title = {Pharmacology of orismilast, a potent and selective PDE4 inhibitor},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.18818}
}
Kostenlos starten →